Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review

The introduction of novel therapeutic agents for advanced prostate cancer has led to a wide range of treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC). In the past decade, new treatment options for mCRPC, including abiraterone, enzalutamide, docetaxel, cabaz...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatano, Koji, Nonomura, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Sexual Medicine and Andrology 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523115/
https://www.ncbi.nlm.nih.gov/pubmed/36792090
http://dx.doi.org/10.5534/wjmh.220200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523115/
https://www.ncbi.nlm.nih.gov/pubmed/36792090
http://dx.doi.org/10.5534/wjmh.220200

Ejemplares similares